6 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#SideEffects #Table ... #DecisionAid #Orals ... #DM2 #Diabetes ... #Endocrinology # ... Pharmacology #Management
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Summary Table ... Insulin Lifestyle ... events TZDs DPP ... #management #endocrinology ... #dm2
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD, DPP ... Diabetes #Mellitus #DM2 ... #pharmacology # ... comparison #table ... #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
-> Stimulates Insulin ... will stimulate insulin ... Renal #Dosing #Pharmacology ... Management #Diabetes #DM2 ... #Endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
for insulin. ... There is an ORAL ... very similar to DPP4s ... Dosing #Diabetes #DM2 ... #Endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... drug to remain stable ... empagliflozin and DPP4 ... semaglutide #Diabetes #Pharmacology ... #Endocrinology